Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study.

Autor: Gradišer M; Internal Medicine Ward, General Hospital Čakovec, Čakovec, Croatia., Berković MC; Department for Endocrinology, Diabetes and Metabolism, University Hospital Centre 'Sestre Milosrdnice', Zagreb, Croatia., Bilić-Ćurčić I; Department of Pharmacology, Faculty of Medicine, University J.J. Strossmayer, Osijek, Clinical Hospital Center Osijek, Croatia. Electronic address: ibcurcic@mefos.hr.
Jazyk: angličtina
Zdroj: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2017 Jul; Vol. 129, pp. 144-147. Date of Electronic Publication: 2017 May 09.
DOI: 10.1016/j.diabres.2017.03.036
Abstrakt: We included diabetes type 1 (T1DM) patients with suboptimal glycemic control on morning application glargine (I-Glar) U100, switching them to U300. After six months improvement in HbA1c was observed, while hypoglycemic episodes decreased. Switch from I-Glar U100 to U300 could be a good therapeutic option for that subset of patients.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: